Report Cover

Antiviral Drugs Market Size By Drug Class (DNA Polymerase Inhibitors, Reverse Transcriptase Inhibitors, Protease Inhibitors, Neuraminidase Inhibitors), By Indication (Influenza, HIV AIDS, Hepatitis, Herpes Simplex Virus [HSV], Coronavirus Infection), By Type (Branded, Generic), By Age Group (Pediatric, Adult, Geriatric), Industry Analysis Report, Regional Outlook, Type Potential, Price Trends, Competitive Market Share & Forecast, 2021 - 2027


The anti-viral drugs market is likely to witness exponential growth over the forecast time period owing to large patient pool suffering from COVID-19 infection, increasing prevalence of sexually transmitted diseases, and instances of seasonal flu across the U.S. Antiviral drugs are usually prescription medicines that efficiently fight against viruses in the body. 

These come in inhaled powder form, liquid form, and pills form. When utilized as directed, these drugs aid in reducing the duration of flu symptoms in otherwise healthy children as well as adults and might also reduce the danger of common flu symptoms.

Increasing CVOVID-19 cases across the world is further driving the demand for anti-viral drugs. As per mortality surveillance data of NCHS on 25th February 2021, nearly 19.3 per cent of the deaths that happened in the week ending 20th February 2021 were mainly because of COVID-19, influenza, and pneumonia. In fact, Remdesivir is the only anti-viral drug approved by the FDA for the treatment of SARS-CoV-2 virus or COVID-19. 

The anti-viral drugs market is bifurcated into various segments in terms of drug class, indication, type, age group, and regional landscape. 

Based on drug class the market for anti-viral drugs are classified into neuraminidase inhibitors, protease inhibitors, reverse transcriptase inhibitors, DNA polymerase inhibitors, and others. In 2020, the others segment accounted for $5 billion and will follow similar growth over the coming years. The segmental growth is attributed to the increasing use of combination therapy for more effectivity in treatment. 

In terms of indication the overall market is bifurcated into coronavirus infection, HSV (herpes simplex virus), hepatitis, HIV AIDS, influenza, and others. Among these, the influenza segment is likely to witness a CAGR of over -4.3% through the forecast time period. This earmarked growth is ascribed to occurrence of seasonal flu in U.S. along with changing strain and the requirement for new drugs. 

With respect to type the anti-viral market is divided into generic and branded. In 2020, the branded segment accounted for an overall market share of 70% and is estimated to follow a strong growth trend over the coming years. Greater efficacy of branded drugs coupled with manufacture of these branded drugs by major industry players is anticipated to drive the segment growth. 

In terms of age group, the overall anti-viral drugs market is segmented into geriatric, pediatric, and Adult. Among these, adult segment held over 32% share in 2020 and will showcase robust growth over the coming time period. This projected growth is ascribed to the increasing prevalence of sexually transmitted diseases in adults and considerable cost of therapy. 

From a regional frame of reference, North America anti-viral drugs market is expected to witness strong growth over the forecast period. This anticipated growth is ascribed to major factors such as large pool suffering from COVID-19 infection and high presence of major manufacturers of COVID-19 as well as HIV drugs.
Report Content
Chapter 1   Methodology 
1.1    Market definitions
1.2    Base estimates and working
1.2.1    North America
1.2.2    Europe
1.2.3    Asia Pacific
1.2.4    Latin America
1.2.5    MEA
1.3    Forecast calculations
1.4    Data validation
1.5    Data sources
1.5.1    Secondary
1.5.1.1    Paid sources
1.5.1.2    Unpaid sources
1.5.2    Primary
Chapter 2   Executive Summary
2.1    Anti-viral drugs market industry 360 degree synopsis
2.1.1    Business trends
2.1.2    Drug class trends
2.1.3    Indication trends
2.1.4    Type trends
2.1.5    Age group trends
2.1.6    Regional trends
Chapter 3   Anti-viral Drugs Market Industry Insights
3.1    Industry segmentation
3.2    Industry landscape, 2016 - 2027 (USD Million)
3.3    Industry impact forces
3.3.1    Growth drivers
3.3.1.1    Increasing prevalence of viral infections including COVID-19
3.3.1.2    Presence of pipeline products for HIV treatment
3.3.1.3    Increasing geriatric population
3.3.2    Industry pitfalls & challenges
3.3.2.1    Presence of generics
3.3.2.2    Rising awareness about preventive drugs treatment
3.3.2.3    Drug resistance
3.4    Growth potential analysis
3.4.1    By drug class
3.4.2    By indication
3.4.3    By drug class
3.4.4    By age group
3.5    COVID-19 impact analysis
3.6    Regulatory landscape
3.7    Reimbursement scenario
3.8    Porter's analysis
3.9    Competitive landscape, 2020
3.10    PESTEL analysis
Chapter 4   Anti-viral Drugs Market, By Drug Class
4.1    Key segment trends
4.2    DNA polymerase inhibitors
4.2.1    Market size, by region, 2016 - 2027 (USD Million)
4.3    Reverse transcript inhibitors
4.3.1    Market size, by region, 2016 - 2027 (USD Million)
4.4    Protease inhibitors
4.4.1    Market size, by region, 2016 - 2027 (USD Million)
4.5    Neuraminidase Inhibitors
4.5.1    Market size, by region, 2016 - 2027 (USD Million)
4.6    Others
4.6.1    Market size, by region, 2016 - 2027 (USD Million)
Chapter 5   Anti-viral Drugs Market, By Indication
5.1    Key segment trends
5.2    Influenza
5.2.1    Market size, by region, 2016 - 2027 (USD Million)
5.3    HIV AIDS
5.3.1    Market size, by region, 2016 - 2027 (USD Million)
5.4    Hepatitis
5.4.1    Market size, by region, 2016 - 2027 (USD Million)
5.5    Herpes simplex virus (HSV)
5.5.1    Market size, by region, 2016 - 2027 (USD Million)
5.6    Coronavirus infection
5.6.1    Market size, by region, 2016 - 2027 (USD Million)
5.7    Others
5.7.1    Market size, by region, 2016 - 2027 (USD Million)
Chapter 6   Anti-viral Drugs Market, By Type
6.1    Key segment trends
6.2    Branded
6.2.1    Market size, by region, 2016 - 2027 (USD Million)
6.3    Generic
6.3.1    Market size, by region, 2016 - 2027 (USD Million)
Chapter 7   Anti-viral Drugs Market, By Age Group
7.1    Key segment trends
7.2    Adult
7.2.1    Market size, by region, 2016 - 2027 (USD Million)
7.3    Pediatric
7.3.1    Market size, by region, 2016 - 2027 (USD Million)
7.4    Geriatric
7.4.1    Market size, by region, 2016 - 2027 (USD Million)
Chapter 8   Anti-viral Drugs Market, By Region
8.1    Key regional trends
8.2    North America
8.2.1    Market size, by country, 2016 - 2027 (USD Million)
8.2.2    Market size, by drug class, 2016 - 2027 (USD Million)
8.2.3    Market size, by indication, 2016-2027 (USD Million)
8.2.4    Market size, by type, 2016-2027 (USD Million)
8.2.5    Market size, by age group, 2016 - 2027 (USD Million)
8.2.6    U.S.
8.2.6.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.2.6.2    Market size, by indication, 2016 - 2027 (USD Million)
8.2.6.3    Market size, by type, 2016 - 2027 (USD Million)
8.2.6.4    Market size, by age group, 2016 - 2027 (USD Million)
8.2.7    Canada
8.2.7.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.2.7.2    Market size, by indication, 2016 - 2027 (USD Million)
8.2.7.3    Market size, by type, 2016 - 2027 (USD Million)
8.2.7.4    Market size, by age group, 2016 - 2027 (USD Million)
8.3    Europe
8.3.1    Market size, by country, 2016 - 2027 (USD Million)
8.3.2    Market size, by drug class, 2016 - 2027 (USD Million)
8.3.3    Market size, by indication, 2016-2027 (USD Million)
8.3.4    Market size, by type, 2016-2027 (USD Million)
8.3.5    Market size, by age group, 2016 - 2027 (USD Million)
8.3.6    Germany
8.3.6.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.3.6.2    Market size, by indication, 2016 - 2027 (USD Million)
8.3.6.3    Market size, by type, 2016 - 2027 (USD Million)
8.3.6.4    Market size, by age group, 2016 - 2027 (USD Million)
8.3.7    UK
8.3.7.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.3.7.2    Market size, by indication, 2016 - 2027 (USD Million)
8.3.7.3    Market size, by type, 2016 - 2027 (USD Million)
8.3.7.4    Market size, by age group, 2016 - 2027 (USD Million)
8.3.8    France
8.3.8.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.3.8.2    Market size, by indication, 2016 - 2027 (USD Million)
8.3.8.3    Market size, by type, 2016 - 2027 (USD Million)
8.3.8.4    Market size, by age group, 2016 - 2027 (USD Million)
8.3.9    Spain
8.3.9.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.3.9.2    Market size, by indication, 2016 - 2027 (USD Million)
8.3.9.3    Market size, by type, 2016 - 2027 (USD Million)
8.3.9.4    Market size, by age group, 2016 - 2027 (USD Million)
8.3.10    Italy
8.3.10.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.3.10.2    Market size, by indication, 2016 - 2027 (USD Million)
8.3.10.3    Market size, by type, 2016 - 2027 (USD Million)
8.3.10.4    Market size, by age group, 2016 - 2027 (USD Million)
8.3.11    Russia
8.3.11.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.3.11.2    Market size, by indication, 2016 - 2027 (USD Million)
8.3.11.3    Market size, by type, 2016 - 2027 (USD Million)
8.3.11.4    Market size, by age group, 2016 - 2027 (USD Million)
8.3.12    Poland
8.3.12.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.3.12.2    Market size, by indication, 2016 - 2027 (USD Million)
8.3.12.3    Market size, by type, 2016 - 2027 (USD Million)
8.3.12.4    Market size, by age group, 2016 - 2027 (USD Million)
8.3.13    Switzerland
8.3.13.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.3.13.2    Market size, by indication, 2016 - 2027 (USD Million)
8.3.13.3    Market size, by type, 2016 - 2027 (USD Million)
8.3.13.4    Market size, by age group, 2016 - 2027 (USD Million)
8.3.14    Netherlands
8.3.14.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.3.14.2    Market size, by indication, 2016 - 2027 (USD Million)
8.3.14.3    Market size, by type, 2016 - 2027 (USD Million)
8.3.14.4    Market size, by age group, 2016 - 2027 (USD Million)
8.3.15    Sweden
8.3.15.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.3.15.2    Market size, by indication, 2016 - 2027 (USD Million)
8.3.15.3    Market size, by type, 2016 - 2027 (USD Million)
8.3.15.4    Market size, by age group, 2016 - 2027 (USD Million)
8.4    Asia Pacific
8.4.1    Market size, by country, 2016 - 2027 (USD Million)
8.4.2    Market size, by drug class, 2016 - 2027 (USD Million)
8.4.3    Market size, by indication, 2016-2027 (USD Million)
8.4.4    Market size, by type, 2016-2027 (USD Million)
8.4.5    Market size, by age group, 2016 - 2027 (USD Million)
8.4.6    Japan
8.4.6.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.4.6.2    Market size, by indication, 2016 - 2027 (USD Million)
8.4.6.3    Market size, by type, 2016 - 2027 (USD Million)
8.4.6.4    Market size, by age group, 2016 - 2027 (USD Million)
8.4.7    China
8.4.7.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.4.7.2    Market size, by indication, 2016 - 2027 (USD Million)
8.4.7.3    Market size, by type, 2016 - 2027 (USD Million)
8.4.7.4    Market size, by age group, 2016 - 2027 (USD Million)
8.4.8    India
8.4.8.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.4.8.2    Market size, by indication, 2016 - 2027 (USD Million)
8.4.8.3    Market size, by type, 2016 - 2027 (USD Million)
8.4.8.4    Market size, by age group, 2016 - 2027 (USD Million)
8.4.9    Australia
8.4.9.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.4.9.2    Market size, by indication, 2016 - 2027 (USD Million)
8.4.9.3    Market size, by type, 2016 - 2027 (USD Million)
8.4.9.4    Market size, by age group, 2016 - 2027 (USD Million)
8.4.10    South Korea
8.4.10.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.4.10.2    Market size, by indication, 2016 - 2027 (USD Million)
8.4.10.3    Market size, by type, 2016 - 2027 (USD Million)
8.4.10.4    Market size, by age group, 2016 - 2027 (USD Million)
8.4.11    Singapore
8.4.11.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.4.11.2    Market size, by indication, 2016 - 2027 (USD Million)
8.4.11.3    Market size, by type, 2016 - 2027 (USD Million)
8.4.11.4    Market size, by age group, 2016 - 2027 (USD Million)
8.4.12    Indonesia
8.4.12.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.4.12.2    Market size, by indication, 2016 - 2027 (USD Million)
8.4.12.3    Market size, by type, 2016 - 2027 (USD Million)
8.4.12.4    Market size, by age group, 2016 - 2027 (USD Million)
8.4.13    Thailand
8.4.13.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.4.13.2    Market size, by indication, 2016 - 2027 (USD Million)
8.4.13.3    Market size, by type, 2016 - 2027 (USD Million)
8.4.13.4    Market size, by age group, 2016 - 2027 (USD Million)
8.4.14    Malaysia
8.4.14.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.4.14.2    Market size, by indication, 2016 - 2027 (USD Million)
8.4.14.3    Market size, by type, 2016 - 2027 (USD Million)
8.4.14.4    Market size, by age group, 2016 - 2027 (USD Million)
8.4.15    Philippines
8.4.15.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.4.15.2    Market size, by indication, 2016 - 2027 (USD Million)
8.4.15.3    Market size, by type, 2016 - 2027 (USD Million)
8.4.15.4    Market size, by age group, 2016 - 2027 (USD Million)
8.5    Latin America
8.5.1    Market size, by country, 2016 - 2027 (USD Million)
8.5.2    Market size, by drug class, 2016 - 2027 (USD Million)
8.5.3    Market size, by indication, 2016-2027 (USD Million)
8.5.4    Market size, by type, 2016-2027 (USD Million)
8.5.5    Market size, by age group, 2016 - 2027 (USD Million)
8.5.6    Brazil
8.5.6.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.5.6.2    Market size, by indication, 2016 - 2027 (USD Million)
8.5.6.3    Market size, by type, 2016 - 2027 (USD Million)
8.5.6.4    Market size, by age group, 2016 - 2027 (USD Million)
8.5.7    Mexico
8.5.7.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.5.7.2    Market size, by indication, 2016 - 2027 (USD Million)
8.5.7.3    Market size, by type, 2016 - 2027 (USD Million)
8.5.7.4    Market size, by age group, 2016 - 2027 (USD Million)
8.5.8    Argentina
8.5.8.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.5.8.2    Market size, by indication, 2016 - 2027 (USD Million)
8.5.8.3    Market size, by type, 2016 - 2027 (USD Million)
8.5.8.4    Market size, by age group, 2016 - 2027 (USD Million)
8.6    Middle East & Africa
8.6.1    Market size, by country, 2016 - 2027 (USD Million)
8.6.2    Market size, by drug class, 2016 - 2027 (USD Million)
8.6.3    Market size, by indication, 2016-2027 (USD Million)
8.6.4    Market size, by type, 2016-2027 (USD Million)
8.6.5    Market size, by age group, 2016 - 2027 (USD Million)
8.6.6    Saudi Arabia
8.6.6.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.6.6.2    Market size, by indication, 2016 - 2027 (USD Million)
8.6.6.3    Market size, by type, 2016 - 2027 (USD Million)
8.6.6.4    Market size, by age group, 2016 - 2027 (USD Million)
8.6.7    South Africa
8.6.7.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.6.7.2    Market size, by indication, 2016 - 2027 (USD Million)
8.6.7.3    Market size, by type, 2016 - 2027 (USD Million)
8.6.7.4    Market size, by age group, 2016 - 2027 (USD Million)
8.6.8    UAE
8.6.8.1    Market size, by drug class, 2016 - 2027 (USD Million)
8.6.8.2    Market size, by indication, 2016 - 2027 (USD Million)
8.6.8.3    Market size, by type, 2016 - 2027 (USD Million)
8.6.8.4    Market size, by age group, 2016 - 2027 (USD Million)
Chapter 9   Company Profiles
9.1    Competitive dashboard, 2020
9.2    Gilead Sciences, Inc
9.2.1    Business overview
9.2.2    Financial data
9.2.3    Product landscape
9.2.4    Strategic outlook
9.2.5    SWOT analysis
9.3    Johnson & Johnson
9.3.1    Business overview
9.3.2    Financial data
9.3.3    Product landscape
9.3.4    Strategic outlook
9.3.5    SWOT analysis
9.4    GlaxoSmithKline
9.4.1    Business overview
9.4.2    Financial data
9.4.3    Product landscape
9.4.4    Strategic outlook
9.4.5    SWOT analysis
9.5    AbbVie, Inc
9.5.1    Business overview
9.5.2    Financial data
9.5.3    Product landscape
9.5.4    Strategic outlook
9.5.5    SWOT analysis
9.6.     Merck & Co.,
9.6.1    Business overview
9.6.2    Financial data
9.6.3    Product landscape
9.6.4    Strategic outlook
9.6.5    SWOT analysis
9.7    Bristol Myers Squibb
9.7.1    Business overview
9.7.2    Financial data
9.7.3    Product landscape
9.7.4    Strategic outlook
9.7.5    SWOT analysis
9.8    Aurobindo Pharma Limited
9.8.1    Business overview
9.8.2    Financial data
9.8.3    Product landscape
9.8.4    Strategic outlook
9.8.5    SWOT analysis
9.9    Sun Pharmaceutical Industries Ltd
9.9.1    Business overview
9.9.2    Financial data
9.9.3    Product landscape
9.9.4    Strategic outlook
9.9.5    SWOT analysis
9.10    Cipla, Inc.
9.10.1    Business overview
9.10.2    Financial data
9.10.3    Product landscape
9.10.4    Strategic outlook
9.10.5    SWOT analysis
9.11    Mylan N V
9.11.1    Business overview
9.11.2    Financial data
9.11.3    Product landscape
9.11.4    Strategic outlook
9.11.5    SWOT analysis

Data Tables TABLE 1 Anti-viral drugs market, 2016-2027(USD Million) TABLE 2 Anti-viral drugs market, by drug class, 2016-2027(USD Million) TABLE 3 Anti-viral drugs market, by indication, 2016-2027(USD Million) TABLE 4 Anti-viral drugs market, by type, 2016-2027(USD Million) TABLE 5 Anti-viral drugs market, by age group, 2016-2027(USD Million) TABLE 6 Anti-viral drugs market, by region, 2016-2027(USD Million) TABLE 7 Industry impact forces TABLE 8 DNA polymerase inhibitors market size, by region, 2016-2027(USD Million) TABLE 9 Reverse transcriptase inhibitors market size, by region, 2016-2027(USD Million) TABLE 10 Protease inhibitors market size, by region, 2016-2027(USD Million) TABLE 11 Neuraminidase inhibitors market size, by region, 2016-2027(USD Million) TABLE 12 Others market size, by region, 2016-2027(USD Million) TABLE 13 Influenza market size, by region, 2016-2027(USD Million) TABLE 14 HIV AIDS market size, by region, 2016-2027(USD Million) TABLE 15 Hepatitis market size, by region, 2016-2027(USD Million) TABLE 16 Herpes simplex virus market size, by region, 2016-2027(USD Million) TABLE 17 Coronavirus infection market size, by region, 2016-2027(USD Million) TABLE 18 Others market size, by region, 2016-2027(USD Million) TABLE 19 Branded market size, by region, 2016-2027(USD Million) TABLE 20 Generic market size, by region, 2016-2027(USD Million) TABLE 21 Adult market size, by region, 2016-2027(USD Million) TABLE 22 Pediatric market size, by region, 2016-2027(USD Million) TABLE 23 Geriatric market size, by region, 2016-2027(USD Million) TABLE 24 North America market size, by country, 2016 - 2027 (USD Million) TABLE 25 North America market size, by drug class, 2016 - 2027 (USD Million) TABLE 26 North America market size, by indication, 2016 - 2027 (USD Million) TABLE 27 North America market size, by type, 2016 - 2027 (USD Million) TABLE 28 North America market size, by age group, 2016 - 2027 (USD Million) TABLE 29 U.S. market size, by drug class, 2016 - 2027 (USD Million) TABLE 30 U.S. market size, by indication, 2016 - 2027 (USD Million) TABLE 31 U.S. market size, by type, 2016 - 2027 (USD Million) TABLE 32 U.S. market size, by age group, 2016 - 2027 (USD Million) TABLE 33 Canada market size, by drug class, 2016 - 2027 (USD Million) TABLE 34 Canada market size, by indication, 2016 - 2027 (USD Million) TABLE 35 Canada market size, by type, 2016 - 2027 (USD Million) TABLE 36 Canada market size, by age group, 2016 - 2027 (USD Million) TABLE 37 Europe market size, by country, 2016 - 2027 (USD Million) TABLE 38 Europe market size, by drug class, 2016 - 2027 (USD Million) TABLE 39 Europe market size, by indication, 2016 - 2027 (USD Million) TABLE 40 Europe market size, by type, 2016 - 2027 (USD Million) TABLE 41 Europe market size, by age group, 2016 - 2027 (USD Million) TABLE 42 Germany market size, by drug class, 2016 - 2027 (USD Million) TABLE 43 Germany market size, by indication, 2016 - 2027 (USD Million) TABLE 44 Germany market size, by type, 2016 - 2027 (USD Million) TABLE 45 Germany market size, by age group, 2016 - 2027 (USD Million) TABLE 46 UK market size, by drug class, 2016 - 2027 (USD Million) TABLE 47 UK market size, by indication, 2016 - 2027 (USD Million) TABLE 48 UK market size, by type, 2016 - 2027 (USD Million) TABLE 49 UK market size, by age group, 2016 - 2027 (USD Million) TABLE 50 France market size, by drug class, 2016 - 2027 (USD Million) TABLE 51 France market size, by indication, 2016 - 2027 (USD Million) TABLE 52 France market size, by type, 2016 - 2027 (USD Million) TABLE 53 France market size, by age group, 2016 - 2027 (USD Million) TABLE 54 Italy market size, by drug class, 2016 - 2027 (USD Million) TABLE 55 Italy market size, by indication, 2016 - 2027 (USD Million) TABLE 56 Italy market size, by type, 2016 - 2027 (USD Million) TABLE 57 Italy market size, by age group, 2016 - 2027 (USD Million) TABLE 58 Spain market size, by drug class, 2016 - 2027 (USD Million) TABLE 59 Spain market size, by indication, 2016 - 2027 (USD Million) TABLE 60 Spain market size, by type, 2016 - 2027 (USD Million) TABLE 61 Spain market size, by age group, 2016 - 2027 (USD Million) TABLE 62 Russia market size, by drug class, 2016 - 2027 (USD Million) TABLE 63 Russia market size, by indication, 2016 - 2027 (USD Million) TABLE 64 Russia market size, by type, 2016 - 2027 (USD Million) TABLE 65 Russia market size, by age group, 2016 - 2027 (USD Million) TABLE 66 Poland market size, by drug class, 2016 - 2027 (USD Million) TABLE 67 Poland market size, by indication, 2016 - 2027 (USD Million) TABLE 68 Poland market size, by type, 2016 - 2027 (USD Million) TABLE 69 Poland market size, by age group, 2016 - 2027 (USD Million) TABLE 70 Switzerland market size, by drug class, 2016 - 2027 (USD Million) TABLE 71 Switzerland market size, by indication, 2016 - 2027 (USD Million) TABLE 72 Switzerland market size, by type, 2016 - 2027 (USD Million) TABLE 73 Switzerland market size, by age group, 2016 - 2027 (USD Million) TABLE 74 Netherlands market size, by drug class, 2016 - 2027 (USD Million) TABLE 75 Netherlands market size, by indication, 2016 - 2027 (USD Million) TABLE 76 Netherlands market size, by type, 2016 - 2027 (USD Million) TABLE 77 Netherlands market size, by age group, 2016 - 2027 (USD Million) TABLE 78 Sweden market size, by drug class, 2016 - 2027 (USD Million) TABLE 79 Sweden market size, by indication, 2016 - 2027 (USD Million) TABLE 80 Sweden market size, by type, 2016 - 2027 (USD Million) TABLE 81 Sweden market size, by age group, 2016 - 2027 (USD Million) TABLE 82 Asia Pacific market size, by country, 2016 - 2027 (USD Million) TABLE 83 Asia Pacific market size, by drug class, 2016 - 2027 (USD Million) TABLE 84 Asia Pacific market size, by indication, 2016 - 2027 (USD Million) TABLE 85 Asia Pacific market size, by type, 2016 - 2027 (USD Million) TABLE 86 Asia Pacific market size, by age group, 2016 - 2027 (USD Million) TABLE 87 Japan market size, by drug class, 2016 - 2027 (USD Million) TABLE 88 Japan market size, by indication, 2016 - 2027 (USD Million) TABLE 89 Japan market size, by type, 2016 - 2027 (USD Million) TABLE 90 Japan market size, by age group, 2016 - 2027 (USD Million) TABLE 91 China market size, by drug class, 2016 - 2027 (USD Million) TABLE 92 China market size, by indication, 2016 - 2027 (USD Million) TABLE 93 China market size, by type, 2016 - 2027 (USD Million) TABLE 94 China market size, by age group, 2016 - 2027 (USD Million) TABLE 95 India market size, by drug class, 2016 - 2027 (USD Million) TABLE 96 India market size, by indication, 2016 - 2027 (USD Million) TABLE 97 India market size, by type, 2016 - 2027 (USD Million) TABLE 98 India market size, by age group, 2016 - 2027 (USD Million) TABLE 99 Australia market size, by drug class, 2016 - 2027 (USD Million) TABLE 100 Australia market size, by indication, 2016 - 2027 (USD Million) TABLE 101 Australia market size, by type, 2016 - 2027 (USD Million) TABLE 102 Australia market size, by age group, 2016 - 2027 (USD Million) TABLE 103 South Korea market size, by drug class, 2016 - 2027 (USD Million) TABLE 104 South Korea market size, by indication, 2016 - 2027 (USD Million) TABLE 105 South Korea market size, by type, 2016 - 2027 (USD Million) TABLE 106 South Korea market size, by age group, 2016 - 2027 (USD Million) TABLE 107 Singapore market size, by drug class, 2016 - 2027 (USD Million) TABLE 108 Singapore market size, by indication, 2016 - 2027 (USD Million) TABLE 109 Singapore market size, by type, 2016 - 2027 (USD Million) TABLE 110 Singapore market size, by age group, 2016 - 2027 (USD Million) TABLE 111 Indonesia market size, by drug class, 2016 - 2027 (USD Million) TABLE 112 Indonesia market size, by indication, 2016 - 2027 (USD Million) TABLE 113 Indonesia market size, by type, 2016 - 2027 (USD Million) TABLE 114 Indonesia market size, by age group, 2016 - 2027 (USD Million) TABLE 115 Thailand market size, by drug class, 2016 - 2027 (USD Million) TABLE 116 Thailand market size, by indication, 2016 - 2027 (USD Million) TABLE 117 Thailand market size, by type, 2016 - 2027 (USD Million) TABLE 118 Thailand market size, by age group, 2016 - 2027 (USD Million) TABLE 119 Malaysia market size, by drug class, 2016 - 2027 (USD Million) TABLE 120 Malaysia market size, by indication, 2016 - 2027 (USD Million) TABLE 121 Malaysia market size, by type, 2016 - 2027 (USD Million) TABLE 122 Malaysia market size, by age group, 2016 - 2027 (USD Million) TABLE 123 Philippines market size, by drug class, 2016 - 2027 (USD Million) TABLE 124 Philippines market size, by indication, 2016 - 2027 (USD Million) TABLE 125 Philippines market size, by type, 2016 - 2027 (USD Million) TABLE 126 Philippines market size, by age group, 2016 - 2027 (USD Million) TABLE 127 Latin America market size, by country, 2016 - 2027 (USD Million) TABLE 128 Latin America market size, by drug class, 2016 - 2027 (USD Million) TABLE 129 Latin America market size, by indication, 2016 - 2027 (USD Million) TABLE 130 Latin America market size, by type, 2016 - 2027 (USD Million) TABLE 131 Latin America market size, by age group, 2016 - 2027 (USD Million) TABLE 132 Brazil market size, by drug class, 2016 - 2027 (USD Million) TABLE 133 Brazil market size, by indication, 2016 - 2027 (USD Million) TABLE 134 Brazil market size, by type, 2016 - 2027 (USD Million) TABLE 135 Brazil market size, by age group, 2016 - 2027 (USD Million) TABLE 136 Mexico market size, by drug class, 2016 - 2027 (USD Million) TABLE 137 Mexico market size, by indication, 2016 - 2027 (USD Million) TABLE 138 Mexico market size, by type, 2016 - 2027 (USD Million) TABLE 139 Mexico market size, by age group, 2016 - 2027 (USD Million) TABLE 140 Argentina market size, by drug class, 2016 - 2027 (USD Million) TABLE 141 Argentina market size, by indication, 2016 - 2027 (USD Million) TABLE 142 Argentina market size, by type, 2016 - 2027 (USD Million) TABLE 143 Argentina market size, by age group, 2016 - 2027 (USD Million) TABLE 144 MEA market size, by country, 2016 - 2027 (USD Million) TABLE 145 MEA market size, by drug class, 2016 - 2027 (USD Million) TABLE 146 MEA market size, by indication, 2016 - 2027 (USD Million) TABLE 147 MEA market size, by type, 2016 - 2027 (USD Million) TABLE 148 MEA market size, by age group, 2016 - 2027 (USD Million) TABLE 149 South Africa market size, by drug class, 2016 - 2027 (USD Million) TABLE 150 South Africa market size, by indication, 2016 - 2027 (USD Million) TABLE 151 South Africa market size, by type, 2016 - 2027 (USD Million) TABLE 152 South Africa market size, by age group, 2016 - 2027 (USD Million) TABLE 153 Saudi Arabia market size, by drug class, 2016 - 2027 (USD Million) TABLE 154 Saudi Arabia market size, by indication, 2016 - 2027 (USD Million) TABLE 155 Saudi Arabia market size, by type, 2016 - 2027 (USD Million) TABLE 156 Saudi Arabia market size, by age group, 2016 - 2027 (USD Million) TABLE 157 UAE market size, by drug class, 2016 - 2027 (USD Million) TABLE 158 UAE market size, by indication, 2016 - 2027 (USD Million) TABLE 159 UAE market size, by type, 2016 - 2027 (USD Million) TABLE 160 UAE market size, by age group, 2016 - 2027 (USD Million) Charts & Figures FIG. 1 Anti-viral drugs industry 360 degree synopsis, 2016 - 2027 FIG. 2 Industry segmentation FIG. 3 Global anti-viral drugs industry landscape, 2016 - 2027 (USD Million) FIG. 4 Growth potential analysis, by drug class FIG. 5 Growth potential analysis, by indication FIG. 6 Growth potential analysis, by type FIG. 7 Growth potential analysis, by age group FIG. 8 Porter's analysis FIG. 9 PESTEL analysis FIG. 10 Key segment trends, by drug class FIG. 11 Key segment trends, by indication FIG. 12 Key segment trends, by type FIG. 13 Key segment trends, by age group FIG. 14 Key regional trends FIG. 15 Competitive dashboard, 2020

Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:
Publisher: Global Market Insights, Inc.
Chat with us